Indegene Limited has announced the completion of a Trade and Asset Purchase Agreement between its subsidiary Indegene Healthcare UK Limited and Trilogy Writing and Consulting Limited on April 01, 2026. The transaction involves the acquisition of trade and business assets as a going concern, valued at GBP 1,90,679.

Transaction Details

The asset purchase agreement represents a strategic consolidation within the Indegene group structure. Key aspects of the transaction include:

Related Party Transaction

The transaction qualifies as a related party transaction since both entities operate under the same corporate umbrella. The buyer had previously acquired the entire issued share capital of the seller, as disclosed in an intimation filed on March 1, 2026. Both companies are indirectly wholly owned by Indegene Limited, ensuring complete group control over the transaction.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that the related party transaction has been conducted on an arm's length basis, ensuring compliance with regulatory requirements. No special rights such as director appointment rights, share subscription preferences, or capital structure restrictions are associated with this agreement.

Corporate Structure Impact

The asset purchase consolidates business operations within the Indegene group structure. With 100% shareholding in both entities, the transaction represents an internal reorganization that streamlines business assets under unified ownership. The agreement does not involve any share issuance or loan arrangements, maintaining the existing corporate framework while optimizing asset allocation within the group.

Indegene Limited has issued a formal response to the Bombay Stock Exchange (BSE) regarding an inquiry about significant price and volume movements in the company's securities. The clarification, dated March 24, 2026, addresses BSE's concerns under reference number L/SURV/ONL/PV/SG/ 2025-2026 / 996.

Company's Official Response

In its communication to BSE, Indegene confirmed that there is no pending information or undisclosed material event that could significantly impact the price or trading volume of the company's securities as of the date of communication. The company attributed the recent market movements and volatility to prevailing market conditions and investor sentiment rather than any specific corporate developments.

Regulatory Compliance Commitment

The company emphasized its commitment to maintaining transparent and timely disclosures in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Indegene assured that any material developments will be communicated in accordance with applicable regulatory requirements.

Communication Details

The response was digitally signed by Srishti Ramesh Kaushik, who serves as the Company Secretary and Compliance Officer for Indegene Limited. The communication was submitted to BSE's Phiroze Jeejeebhoy Towers office in Mumbai for official records and information purposes.